DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Axicabtagene ciloleucel
Axicabtagene ciloleucel
Chimeric Antigen Receptor T-Cell Therapy – Clinical Guidelines
Axicabtagene Ciloleucel (Yescarta®)
Yescarta™ (Axicabtagene Ciloleucel) – New Orphan Drug Approval
Decision Memo for Chimeric Antigen Receptor (CAR) T-Cell Therapy for Cancers (CAG-00451N)
Cancer Immunotherapy Comes of Age and Looks for Maturity ✉ Amanda Finck1, Saar I
Axicabtagene Ciloleucel, a First-In-Class CAR T Cell Therapy for Aggressive NHL
Prospects for Combined Use of Oncolytic Viruses and CAR T-Cells Adam Ajina1 and John Maher2,3,4*
Drug Price Forecast
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity
PCORI-HCHSS-High Potential Disruption-May-2021
CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation
Effects of the COVID-19 Pandemic on Publication Landscape in Chimeric Antigen Receptor
Table of Contents
Chimeric Antigen Receptor T-Cell (CAR-T) and Advanced Cellular/Immune Effector Cell Therapy
Axicabtagene Ciloleucel (Yescarta) Reference Number: ERX.SPA.221 Effective Date: 10.31.17 Last Review Date: 11.17 Revision Log
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
066 Chimeric Antigen Receptor Therapy for Hematologic Malignancies
Kite a Gileau Company
Top View
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed Or Refractory Large B-Cell Lymphoma Najat Bouchkouj1, Yvette L
Yescarta (Axicabtagene Ciloleucel)
CG063 Yescarta (Axicabtagene Ciloleucel)
July 23, 2020 Summary Basis for Regulatory Action
Yescarta (Axicabtagene Ciloleucel)
Immune Checkpoint Blockade and CAR-T Cell Therapy in Hematologic Malignancies Hao Wang1†, Gurbakhash Kaur2†, Alexander I
Yescarta (Axicabtagene Ciloleucel)
Activation of CAR and Non-CAR T Cells Within the Tumor Microenvironment Following CAR T-Cell Therapy
Parking CAR T Cells in Tumours: Oncolytic Viruses As Valets Or Vandals?
Medical Policy Yescarta (Axicabtagene Ciloleucel)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed Or Refractory Large B-Cell Lymphoma
Hodgkin Lymphoma Marion Masitsa Malenge
Mechanisms of Treatment Resistance in Context of Axicabtagene Ciloleucel for Lymphoma
Tisagenlecleucel for Treating Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma – Second Line
Focus on CAR-T Cell Therapy
Cellular Immunotherapy Manual
Active Immunotherapy in Cancer – Current Status
Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy